Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vidutolimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vidutolimod overview
CMP-001 (CYT-003) is under development for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, head and neck cancer, hepatocellular carcinoma, solid tumors, Oropharyngeal Cancer, oral cavity, hypopharynx, or larynx cancer, metastatic colorectal cancer, advanced cutaneous melanoma, head and neck squamous cell carcinoma, squamous cell carcinoma of the head and neck (SCCHN), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC), metastatic castration resistant prostate cancer and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS). The drug candidate is administered through subcutaneous and intratumoral route. It consists of QbG10 with virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. It acts by targeting Toll-like receptor 9.
It was also under development for the treatment of allergic asthma, triple-negative breast cancer (TNBC), allergic rhinitis, allergic rhinoconjunctivitis, HBV infections, atopic dermatitis, cutaneous squamous cell carcinoma (CSCC), relapsed and refractory B and T cell Hodgkin lymphoma or Non-Hodgkin lymphoma, merkel cell carcinoma, basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC).
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture and commercialize its products. The company sells its products to specialty pharmacies and distributors. It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Vidutolimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
